Literature DB >> 25322968

Purification and immobilization of L-arginase from thermotolerant Penicillium chrysogenum KJ185377.1; with unique kinetic properties as thermostable anticancer enzyme.

Ashraf S El-Sayed1, Ahmed A Shindia, Ayman A Diab, Amgad M Rady.   

Abstract

L-Arginase, hydrolyzing L-arginine to L-ornithine and urea, is a powerful anticancer, L-arginine-depleting agent, against argininosuccinate synthase expressing tumors. Otherwise, the higher antigenicity and lower thermal stability of this enzyme was the main biochemical hurdles. Since, the intrinsic thermal stability of enzymes follow the physiological temperature of their producer, thus, characterization of L-arginase from thermotolerant Penicillium chrysogenum was the objective of this study. L-Arginase (Arg) was purified to its homogeneity from P. chrysogenum by 10.1-fold, with 37.0 kDa under denaturing PAGE, optimum reaction at 50 °C, pH stability (6.8-7.9), with highest molar ratio of constitutional arginine, glutamic acid, lysine and aspartic acid. The purified enzyme was PEGylated and immobilized on chitosan, with 41.9 and 22.1 % yield of immobilization. At 40 °C, the T1/2 value of free-Arg, PEG-Arg and Chit-Arg was 10.4, 15.6, 20.5 h, respectively. The free-Arg and Chit-Arg have a higher affinity to L-arginine (K m 4.8 mM), while, PEG-Arg affinity was decreased by about 3 fold (K m 15.2 mM). The inhibitory constants to the free and PEG-Arg were relatively similar towards HA and PPG. The IC50 for the free enzyme against HEPG-2 and A549 tumor cells was 0.136 and 0.165 U/ml, comparing to 0.232 and 0.496 U/ml for PEG-Arg, respectively. The in vivo T1/2 to the free Arg and PEG-Arg was 16.4 and 20.4 h, respectively as holo-enzyme. The residual L-arginine level upon using free Arg was 156.9 and 144.5 µM, after 6 and 8 h, respectively, regarding to initials at 253.6 µM, while for Peg-Arg the level of L-arginine was nil till 7 h of initial dosing. The titer of IgG was induced by 10-15 % in response to free-Arg after 28 days comparing to IgG titer for PEG-Arg.

Entities:  

Year:  2014        PMID: 25322968     DOI: 10.1007/s12272-014-0498-y

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN: 0253-6269            Impact factor:   4.946


  4 in total

1.  Construction of a highly efficient Bacillus subtilis 168 whole-cell biocatalyst and its application in the production of L-ornithine.

Authors:  Meizhou Wang; Meijuan Xu; Zhiming Rao; Taowei Yang; Xian Zhang
Journal:  J Ind Microbiol Biotechnol       Date:  2015-08-29       Impact factor: 3.346

2.  Intermittent lipid nanoparticle mRNA administration prevents cortical dysmyelination associated with arginase deficiency.

Authors:  Suhail Khoja; Xiao-Bo Liu; Brian Truong; Matthew Nitzahn; Jenna Lambert; Adam Eliav; Eram Nasser; Emma Randolph; Kristine E Burke; Rebecca White; Xuling Zhu; Paolo G V Martini; Itzhak Nissim; Stephen D Cederbaum; Gerald S Lipshutz
Journal:  Mol Ther Nucleic Acids       Date:  2022-04-27       Impact factor: 10.183

Review 3.  Arginine depriving enzymes: applications as emerging therapeutics in cancer treatment.

Authors:  Neha Kumari; Saurabh Bansal
Journal:  Cancer Chemother Pharmacol       Date:  2021-07-26       Impact factor: 3.333

4.  Arginine deaminase from Pseudomonas aeruginosa PS2: purification, biochemical characterization and in-vitro evaluation of anticancer activity.

Authors:  Kiran Bala; Islam Husain; Anjana Sharma
Journal:  3 Biotech       Date:  2020-05-02       Impact factor: 2.406

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.